These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 495334)

  • 21. Correlation between follicle-stimulating hormone, luteinizing hormone, prolactin, and testosterone with sperm cell concentration and motility.
    Vasquez JM; Ben-Nun I; Greenblatt RB; Mahesh VB; Keel BA
    Obstet Gynecol; 1986 Jan; 67(1):86-90. PubMed ID: 3079622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Long-term therapy of oligozoospermia with the aromatase inhibitor testolactone].
    Schill WB; Reiter F; Korting HC; Schweikert HU
    Hautarzt; 1987 Jul; 38(7):395-9. PubMed ID: 3115914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of kallikrein in the treatment of oligozoospermia and asthenozoospermia: a double-blind trial.
    Glezerman M; Lunenfeld E; Potashnik G; Huleihel M; Soffer Y; Segal S
    Fertil Steril; 1993 Dec; 60(6):1052-6. PubMed ID: 8243685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamoxifen and kallikrein in therapy of oligoasthenozoospermia: results of a randomized study.
    Maier U; Hienert G
    Eur Urol; 1990; 17(3):223-5. PubMed ID: 2190839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of hormones on semen parameters in patients with idiopathic or varicocele-related oligoasthenoteratozoospermia (OAT) syndrome.
    Wei TC; Huang WJ; Lin AT; Chen KK
    J Chin Med Assoc; 2013 Nov; 76(11):624-8. PubMed ID: 23933342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of anastrozole in oligozoospermic hypoandrogenic subfertile men.
    Shoshany O; Abhyankar N; Mufarreh N; Daniel G; Niederberger C
    Fertil Steril; 2017 Mar; 107(3):589-594. PubMed ID: 28069178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seminal prostaglandins in men with subnormal sperm motility and therapeutic treatment.
    Schlegel W; Meyer J
    Prostaglandins; 1986 Apr; 31(4):735-44. PubMed ID: 3523625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement of sperm motility in patients with asthenozoospermia by kallikrein treatment.
    Schill WB
    Int J Fertil; 1975; 20(1):61-3. PubMed ID: 4389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between human seminal kallikrein-kinin system and spermatogenesis.
    Kumamoto Y; Saito S; Ito N; Shimamoto K; Iimura O
    Adv Exp Med Biol; 1989; 247A():567-72. PubMed ID: 2603824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of human sperm DNA fragmentation index (DFI) related factors: a report of 1010 subfertile men in China.
    Lu JC; Jing J; Chen L; Ge YF; Feng RX; Liang YJ; Yao B
    Reprod Biol Endocrinol; 2018 Mar; 16(1):23. PubMed ID: 29540184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reinitiation of sperm production in gonadotropin-suppressed normal men by administration of follicle-stimulating hormone.
    Matsumoto AM; Karpas AE; Paulsen CA; Bremner WJ
    J Clin Invest; 1983 Sep; 72(3):1005-15. PubMed ID: 6411766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters in men with idiopathic oligozoospermia.
    Farmakiotis D; Farmakis C; Rousso D; Kourtis A; Katsikis I; Panidis D
    Fertil Steril; 2007 Oct; 88(4):847-53. PubMed ID: 17412336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selection of oligozoospermic men for tamoxifen treatment by an antiestrogen test.
    Schill WB; Schillinger R
    Andrologia; 1987 Jun; 19 Spec No():266-72. PubMed ID: 3115147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of kallikrein in the treatment of oligoasthenospermia].
    Mićić S; Bila S; Ilić V; Sulović V
    Srp Arh Celok Lek; 1985 Apr; 113(4):365-70. PubMed ID: 3901319
    [No Abstract]   [Full Text] [Related]  

  • 36. The level of adrenomedullin immunoreactivity in seminal fluid is higher in oligozoospermic subjects and correlates with semen biochemical parameters.
    Marinoni E; Vellucci O; Letizia C; Sessa M; Moscarini M; Di Iorio R
    Eur J Obstet Gynecol Reprod Biol; 2007 Apr; 131(2):169-75. PubMed ID: 16854513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Penetration capacity of spermatozoa from patients with oligoasthenoteratozoospermia into bovine cervical mucus before and after therapy with kallikrein.
    Maier U; Eisenmenger M
    Arch Androl; 1994; 33(2):67-70. PubMed ID: 7818373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Müllerian hormone in seminal plasma and serum: association with sperm count and sperm motility.
    Andersen JM; Herning H; Witczak O; Haugen TB
    Hum Reprod; 2016 Aug; 31(8):1662-7. PubMed ID: 27220981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapy of idiopathic astheno- and oligozoospermia with pentoxifylline].
    Schill WB
    Fortschr Med; 1982 Apr; 100(15):696-700. PubMed ID: 7084857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Systemic therapy of male subfertility].
    Maier U
    Wien Klin Wochenschr; 1989 Oct; 101(19):673-9. PubMed ID: 2618055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.